Permira to buy small molecule company Cambrex for £1.97bn

This article was originally published here

As per terms of the merger deal, Cambrex shareholders will secure $60 (£49.3) in cash for each share of Cambrex common stock, representing a 47.1% premium to its

The post Permira to buy small molecule company Cambrex for £1.97bn appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply